The Treatment of severe aortic stenosis has experienced a significant revolution with TAVR, especially in high and intermediate risk patients, and it is now extending to low risk patients. In the US, nearly half of patients under 64 are being treated with TAVR. One of the fundamental questions that still remains unanswered revolves around device<a href="https://solaci.org/en/2024/02/14/tavr-in-low-risk-patients-10-year-evolution/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) has widely demonstrated its significant benefits, both in high-risk and inoperable patients, as well as in those with intermediate and low risk. While paravalvular regurgitation has been a challenge, its management has improved with operator experience and a deeper understanding of CT angiographies. However, in cases of regurgitation, elevated gradient,<a href="https://solaci.org/en/2024/02/01/does-post-dilation-in-tavr-affect-its-long-term-outcomes/" title="Read more" >...</a>
Failure of a mitral bioprosthesis always poses a challenge regarding decision-making, especially when dealing with elderly patients with multiple risk factors. The scenario is worsened by the high risk associated with a new sternotomy and the significant impact of undergoing new surgery. Transcatheter mitral valve-in-valve (TMViV) replacement is emerging as a valid strategy in the<a href="https://solaci.org/en/2024/02/01/promising-results-of-transcatheter-mitral-valve-replacement-in-bioprosthesis-failure/" title="Read more" >...</a>
Short dual antiplatelet therapy (DAPT) has shown benefits in patients receiving drug eluting stents (DES), reducing bleeding with no concomitant increase in major adverse cardiovascular events (MACE). Traditionally, the therapeutic window was limited to monotherapy with P2Y12 inhibitors during the first year and there are few data on short DAPT followed by long term monotherapy<a href="https://solaci.org/en/2024/01/29/clopidogrel-monotherapy-beyond-12-months-long-term-analysis-of-the-stopdapt-2/" title="Read more" >...</a>
The effects of diabetes on patients with coronary artery disease are well-known, and their outcomes after angioplasty are less favorable, with a higher rate of restenosis, recurrent acute myocardial infarction, and stent thrombosis. Despite advances in drug-eluting stents and procedural techniques, the treatment of coronary bifurcation lesions in diabetic patients shows less positive clinical outcomes<a href="https://solaci.org/en/2024/01/18/long-term-results-of-coronary-bifurcation-lesion-treatment-in-diabetic-patients/" title="Read more" >...</a>
Both Acurate Neo2 and its predecessor, Acurate Neo, have proven their safety and efficacy in the percutaneous treatment of severe aortic stenosis. The Acurate platform offers a lower gradient and a larger effective orifice area, as well as a low risk of periprocedural complications, according to previous registries. However, the first-generation Acurate device had some<a href="https://solaci.org/en/2024/01/12/acurate-neo2-one-year-hemodynamic-and-clinical-benefit-results/" title="Read more" >...</a>
The use of ultravascular ultrasound (IVUS) to guide coronary angioplasty procedures (PCI) has been shown to reduce the risk of major adverse events in numerous randomized controlled studies, registries and meta-analysis. The current guidelines recommend the use of IVUS in left main disease and complex lesions. The proportion of complex PCI procedures has increased over<a href="https://solaci.org/en/2024/01/09/use-of-ivus-in-complex-pci-results-according-to-operator-experience/" title="Read more" >...</a>
Severe tricuspid regurgitation (TR) presents a reserved prognosis when not treated in time, seeing as systemic venous congestion might significantly limit quality of life in these patients. For many years it was thought diuretic therapy was the only option to treat these patients, since the surgical alternative offered suboptimal results and many patients were deemed<a href="https://solaci.org/en/2023/12/11/heterotopic-tricuspid-intervention-tricvalve-one-year-outcomes/" title="Read more" >...</a>
Approximately 30% of patients undergoing percutaneous coronary intervention (PCI) present moderate to severe calcified lesions, which presents a significant challenge involving a high incidence of major adverse cardiovascular events (MACE). Rotational atherectomy (RA) is used to modify these calcified lesions and facilitate balloon angioplasty followed by stent implantation. The combination of RA with other plaque<a href="https://solaci.org/en/2023/11/30/rotacut-study-rotational-atherectomy-with-cutting-balloon-for-stent-expansion-optimization/" title="Read more" >...</a>
The use of drug-coated balloons (DCB) offers the advantage of avoiding permanent stent implants, thus reducing the incidence of in-stent restenosis (ISR), neoatherosclerosis, and late in-stent thrombosis. Additionally, the use of DCB reduces the duration of dual antiplatelet therapy. Current evidence supports the use of DCB for ISR treatment (Class I) compared with drug-eluting stents<a href="https://solaci.org/en/2023/11/28/drug-coated-balloons-dcb-sirolimus-vs-paclitaxel-in-de-novo-lesions-in-small-vessels/" title="Read more" >...</a>